Dr. Thomas Dayspring - World-Renowned Expert in Lipidology скачать в хорошем качестве

Dr. Thomas Dayspring - World-Renowned Expert in Lipidology

Dr. Thomas Dayspring, MD, FACP, FNLA, is a world-renowned expert in lipidology and cardiovascular prevention. With over 40 years of clinical and academic experience, he has delivered 4,000+ lectures globally and authored over 50 scientific publications. He has received multiple prestigious awards, including the NLA President’s Service Award (2011) and the NLA Clinician/Educator Award (2023). Dr. Dayspring is widely regarded as a leading authority on lipoprotein metabolism, atherothrombosis, and advanced cardiovascular risk assessment, and is known for translating complex lipid science into practical strategies for clinicians. His work has had a profound impact on how cardiovascular risk is evaluated and managed in preventive medicine. Dr. Thomas Dayspring Twitter/X: https://x.com/Drlipid linkedin   / thomas-dayspring-md-facp-fnla-3aaa876   00:00 Introduction 01:00 Types of LDL Cholesterol 01:52 Classes of Lipoprotein 02:19 ApoB Groups by Buoyancy 02:51 Plasma Residence Time 04:00 LDL Particle Number and ApoB Count 05:13 LDL Cholesterol: Correlation and Discordance with ApoB 09:46 Small LDL vs. Large LDL 14:47 Lipoprotein(a) [Lp(a)] 19:40 Oxidized LDL and Clinical Relevance 21:02 Should People with Borderline Hyperlipidemia Test for FH? 28:52 Familial Hypercholesterolemia (FH) 31:03 Treatment Differences: Hyperlipidemia vs FH 34:27 Ideal Levels for LDL Particles and ApoB 38:12 Recommended Laboratory Markers 42:59 Why Lp(a) Cannot Be Converted 45:23 Normal Levels for Lp(a) 46:29 High Lp(a) and Risk of Disease 48:43 Fluctuation in Lp(a) Levels 50:42 Factors Influencing Lipid Profile Accuracy 52:21 PCSK9 Inhibitors, ApoB, Lp(a), and Ongoing Trials 55:18 First-Line Treatment: High ApoB + High Lp(a) 56:43 Starting PCSK9 Inhibitor in High ApoB + High Lp(a) 57:26 Role of Statins When PCSK9 Lowers ApoB 58:01 Side Effects of Lipid Therapies 58:50 Two Classes of PCSK9 Inhibitors 01:00:30 Challenges in Clearing Lp(a) 01:01:18 Therapies Preventing Lp(a) Production 01:04:10 Most Potent ApoB-Lowering Agents 01:05:11 Inclisiran 01:06:28 Does Lowering LDL Cholesterol Affect the Brain? 01:09:25 ApoB Targets 01:10:44 PCSK9 Inhibitors Frequency, Individualization, and Upcoming Oral CETP Inhibitors 01:15:05 Monoclonal Antibodies vs siRNA (Inclisiran) 01:16:15 Isolated High Lp(a) with Normal ApoB 01:19:05 Lifestyle Interventions for Hyperlipidemia 01:20:33 Can Weight Loss Temporarily Raise LDL-C or ApoB? 01:21:31 Statins and Lp(a) 01:22:59 Hypertension and ApoB 01:26:05 Is There a Harmful Level of LDL-C or ApoB Reduction? 01:28:02 Over-Synthesizers vs Over-Absorbers: Therapeutic Approaches 01:32:29 Favorite Therapies / Combinations 01:34:43 Hyperlipidemia: Genetic vs Lifestyle 01:37:36 Environmental Toxins and Lipids 01:39:05 Should We Try Lifestyle Before Medications? 01:40:13 Reversing Atherosclerosis and Vulnerable Sites 01:43:08 Can We Increase LDL Receptors? 01:48:37 Statin Dosing Strategies and Secondary Prevention 01:50:59 HDL Functionality — How to Measure It 01:56:09 Inherited Lp(a): One or Both Parents? 01:58:15 Dietary Fats and Hyperlipidemia 02:01:30 Omega-3 in Lipid Management 02:06:49 Intermittent Fasting and Lipids 02:07:38 Colchicine in Reducing MACE 02:09:18 Dr. Dayspring’s Twitter/X: @DrLipid 02:09:41 Closing Remarks